Bio-Path Holdings Files 8-K on Financials
Ticker: BPTH · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
Related Tickers: BPTH
TL;DR
BPTH filed an 8-K on Aug 15 detailing financials. Check for updates.
AI Summary
Bio-Path Holdings, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Bellaire, Texas.
Why It Matters
This 8-K filing provides investors with crucial updates on Bio-Path Holdings' financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial condition and results of operations, with no immediate indication of significant new risks.
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- August 15, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Bio-Path Holdings, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Bio-Path Holdings, Inc., and it also includes Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on August 15, 2024.
In which state is Bio-Path Holdings, Inc. incorporated?
Bio-Path Holdings, Inc. is incorporated in Delaware.
What is the address of Bio-Path Holdings, Inc.'s principal executive offices?
The address of Bio-Path Holdings, Inc.'s principal executive offices is 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
What is the SIC code for Bio-Path Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Bio-Path Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-15 07:30:23
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20240815x8k.htm (8-K) — 39KB
- bpth-20240815xex99d1.htm (EX-99.1) — 24KB
- bpth-20240815xex99d1001.jpg (GRAPHIC) — 11KB
- 0001558370-24-012293.txt ( ) — 201KB
- bpth-20240815.xsd (EX-101.SCH) — 3KB
- bpth-20240815_lab.xml (EX-101.LAB) — 16KB
- bpth-20240815_pre.xml (EX-101.PRE) — 10KB
- bpth-20240815x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. The information in this Current Report on Form 8-K (this "Current Report") is being furnished pursuant to Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended. On August 15, 2024, Bio-Path Holdings, Inc. (the "Company") issued a press release announcing financial results for the quarter ended June 30, 2024. Additional information is included in the Company's press release. A copy of the Company's press release is attached hereto as Exhibit 99.1. The foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated August 15, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: August 15, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer